- What is XTL Biopharmaceuticals' primary focus?
- XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs, particularly in autoimmune diseases.
- What is the status of XTL Biopharmaceuticals' hCDR1 peptide?
- XTL Biopharmaceuticals' hCDR1 peptide, a compound for treating systemic lupus erythematosus (SLE), has completed three clinical trials involving over 400 patients.
- What is the purpose of XTL Biopharmaceuticals' recombinant erythropoietin compound?
- XTL Biopharmaceuticals is developing recombinant erythropoietin to potentially help advanced-stage multiple myeloma patients live longer with a better quality of life.
- What is the status of XTL Biopharmaceuticals' SAM-101 product?
- XTL Biopharmaceuticals' SAM-101, a proprietary combination of antipsychotic drugs for psychotic diseases like schizophrenia, has completed a phase 2a study at the Shalvata Medical Center.
- When was XTL Biopharmaceuticals founded?
- XTL Biopharmaceuticals was founded in March 1993.
- How many employees does XTL Biopharmaceuticals have?
- XTL Biopharmaceuticals has 1-10 employees.
- What is XTL Biopharmaceuticals' total funding raised to date?
- XTL Biopharmaceuticals has raised a total of $30,040,000 in funding.
- When was XTL Biopharmaceuticals' most recent funding round?
- XTL Biopharmaceuticals' most recent funding round occurred in August 2024, raising $1,500,000.
- What is XTL Biopharmaceuticals' current market capitalization?
- XTL Biopharmaceuticals has a market capitalization of $6,084,460.
- When did XTL Biopharmaceuticals go public on NASDAQ?
- XTL Biopharmaceuticals went public on NASDAQ in September 2005.